Genworth Earnings Call: Enact Strength, LTC Drag

Genworth Financial Inc ((GNW)) has held its Q4 earnings call. Read on for the main highlights of the call.

Genworth Financial’s latest earnings call struck a cautiously optimistic tone as management highlighted strong performance from Enact, accelerated capital returns, and rapid momentum at CareScout. These bright spots were set against sizable long-term care losses, persistent quarterly volatility in the Closed Block, and tight holding company liquidity, leaving investors balancing growth initiatives with ongoing balance sheet pressure.

Enact’s Earnings Power Bolsters Genworth Results

Enact remained the profit engine, contributing $146 million to Genworth’s adjusted operating income in Q4 and $558 million for full-year 2025. Genworth’s share of Enact’s book value, including AOCI, climbed to $4.4 billion from $4.1 billion a year earlier, underscoring the mortgage insurance subsidiary’s growing economic importance.

Robust Capital Returns Flowing Up From Enact

Genworth received $127 million of capital from Enact in Q4 and $407 million over 2025, helping to fund buybacks and strategic investments. With Enact authorizing a $500 million repurchase program and signaling similar capital returns in 2026, Genworth expects roughly $405 million of cash based on its 81% ownership stake.

Share Repurchases Drive Meaningful Equity Shrink

The company continued to aggressively shrink its equity base, repurchasing $245 million of stock in 2025, including $94 million in Q4 at an average price of $8.66 per share. Additional buybacks of $38 million through Feb. 20, 2026 bring total repurchases since May 2022 to about $828 million, cutting shares outstanding roughly 24% from 511 million to 388 million.

CareScout Network Expansion Delivers Rapid Scaling

CareScout posted rapid operational growth as its Quality Network expanded to roughly 790 home care providers across more than 1,000 locations. Coverage now reaches about 97% of the U.S. population aged 65 and older, and CareScout facilitated 925 matches in Q4 and 3,255 in 2025, tripling volume versus 2024 and surpassing its updated targets.

New CareScout Product Launch and Revenue Ambitions

Management emphasized the launch of the Care Assurance long-term care product in Q4, now live in 40 states with four more pending approval. For 2026, CareScout services are targeting around 7,500 matches and at least $25 million in revenue, supported by a planned $50 million to $55 million investment in the services platform.

Portfolio Yields and Alternatives Support Investment Income

Genworth’s investment portfolio remains a quiet tailwind, with new money yields in the life companies around 6.5% during the quarter. The alternative asset program delivered roughly a 9% return for the year, and reinvestment yields exceeded those on maturities and sales, lending support to spread income in a higher-rate environment.

Progress on Closed Block Rate Actions

Within the Closed Block, management pointed to continued risk mitigation through its multi-year rate action program, which has generated about $34.5 billion in net present value since 2012. In 2025 alone, Genworth achieved roughly $209 million of gross incremental long-term care premium approvals, including $100 million in Q4, with average premium increases of 38% for the year.

Debt Profile Stable but Capital Structure Still Stretched

The holding company ended 2025 with $234 million in cash and liquid assets and retired about $7 million of principal, reducing holding company debt to $783 million. Cash interest coverage on debt service stands near 8 times, signaling manageable servicing capacity even as absolute leverage and liquidity remain key watchpoints.

Closed Block Losses Continue to Pressure Earnings

The legacy Closed Block remained a significant drag, posting an adjusted operating loss of $114 million in Q4 and $317 million for the full year. Long-term care was the main driver, with an adjusted operating loss of $159 million in Q4 and $326 million for 2025, overshadowing the strong contributions from Enact.

Adverse LTC Experience and Assumption Updates Hit Results

Genworth reported a pretax unfavorable actual versus expected variance of $124 million in the long-term care block, driven by higher claims and lower terminations in capped cohorts. Additional remeasurement and assumption updates layered in further losses, magnifying the impact on Closed Block results and highlighting the sensitivity of the portfolio to experience trends.

Persistent Quarterly Volatility Under LDTI

Since adopting LDTI, Closed Block actual versus expected losses averaged about $75 million per quarter in 2025, and management cautioned that similar quarterly losses could persist into 2026. This pattern suggests investors should brace for ongoing volatility in reported GAAP earnings, even as management pursues pricing and risk-mitigation actions.

Liquidity Constraints Limit Optionality at the HoldCo

Holding company liquidity remains a constraint, with $234 million of cash and liquid assets at year-end 2025 but roughly $127 million effectively earmarked for future obligations. That leaves limited dry powder for incremental investments or opportunistic capital deployment beyond planned buybacks and required commitments.

Corporate Segment Losses Reflect Strategic Investment Spend

Corporate and Other posted an adjusted operating loss of $24 million in Q4 and $97 million for the full year, reflecting both ongoing investment in CareScout and interest expense on holding company debt. While these losses weigh on consolidated results, management framed them as the cost of building CareScout into a meaningful future earnings contributor.

Regulatory Capital Under Pressure From Higher Requirements

GLIC’s consolidated risk-based capital ratio slipped to 300% at year-end 2025 from 306% a year earlier, driven largely by higher required capital. Increased exposure to limited partnership investments contributed to that capital compression, underscoring regulatory and capital management as ongoing themes for the long-term care insurance platform.

Guidance Highlights: Capital Returns and CareScout Growth

For 2026, Genworth is leaning into capital returns and CareScout expansion, expecting roughly $500 million of capital returned by Enact, of which about $405 million should accrue to Genworth. Management plans to repurchase between $175 million and $225 million of shares in 2026, while CareScout targets around 7,500 matches and at least $25 million of services revenue, supported by $50 million to $55 million of new investment.

Genworth’s call framed a company in transition, with Enact and CareScout increasingly defining the growth story while legacy long-term care and liquidity constraints continue to weigh on headline results. For investors, the trade-off is clear: strong capital generation and buybacks today against lingering volatility and capital intensity in the Closed Block, supporting a constructive yet measured stance on the stock.